- Amgen deploys patients to defend troubled Tavneos in FDA hearing requestFacing pressure around the world to withdraw the rare kidney disease drug Tavneos, Amgen has launched a robust defense with real-world evidence to support the product’s benefit-risk profile.BioSpace · 3d ago↗ source
- Novo asks court to block Lilly ads; Merck strikes HIV PrEP dealPlus news about Abbvie and Genmab, Johnson & Johnson and Mannkind. Novo urges court to block Lilly’s GLP-1 ads: Novo Nordisk asked a New Jersey federal court on Friday to temporarily block wh…Endpoints · 3d ago↗ source
- CHMP recommends Minoryx’s ALD drug, rejects Zevra’s MeplyffaMinoryx Therapeutics finally scored backing from EU regulators for its neurological drug that’s faced multiple hurdles. Meanwhile, Zevra’s rare disease drug got a setback in Europe almost two years…